This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Monteith, D. K. Articles by Levin, A. A. Search for Related Content PubMed PubMed Citation Articles by Monteith, D. K. Articles by Levin, A. A. Social Bookmarking                   What's this?

Synthetic Oligonucleotides: The Development of Antisense Therapeutics

Isis Pharmaceuticals, 2292 Faraday Avenue, Carlsbad, California 92008, dmonteith{at}isisph.com.

Arthur A. Levin

Isis Pharmaceuticals, Carlsbad, California 92008

Antisense therapeutics using synthetic oligodeoxynucleotides (ODNs) are currently being evaluated in clinical trials for cancer, inflammation, and viral diseases. These macromolecules afford a unique opportunity to treat disease at the molecular level. The specificity of these compounds is derived from the genetic code and Watson-Crick base pairing, utilizing an antisense paradigm for the inhibition of translation and the regulation of protein expression. Currently, most antisense ODNs in development contain a phosphorothioate (P=S) backbone. Additional modifications primarily involve the 2' position on the ribose or modification of the nucleotide linkages of the backbone. To date, no toxicities in animal models appear related to inhibition of the pharmacologic target, rather toxicities induced by P=S ODNs appear similar and are independent of pharmacologic target. In general, toxicities correlate well with pharmacokinetic or tissue distribution parameters. In primates, the primary acute effects are associated with complement activation and the systemic effects associated with accumulation of high concentrations of P=S ODNs in the kidneys. In rodents, the primary effect is an immune stimulation characterized by splenomegaly, lymphoid hyperplasia, and mononuclear cell infiltrates in multiple tissues. At extraordinarily high doses (15-50 times the targeted clinical doses), hepatocellular and renal tubular degeneration are evident in rodents. Second generation antisense compounds, new routes of administration, and new formulations appear to broaden and improve the application of antisense technology.

Key Words: Phosphorothioate oligonucleotides • antisense

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. M. Krieg Antiinfective Applications of Toll-like Receptor 9 Agonists Proceedings of the ATS, July 1, 2007; 4(3): 289 - 294. [Abstract] [Full Text] [PDF]

				K. Hayashi, H. Banno, K. Kadomatsu, Y. Takei, K. Komori, and T. Muramatsu Antisense oligodeoxyribonucleotide as to the growth factor midkine suppresses neointima formation induced by balloon injury Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2203 - H2209. [Abstract] [Full Text] [PDF]

				S. Wasmuth, D. Bauer, Y. Yang, K.-P. Steuhl, and A. Heiligenhaus Topical Treatment with Antisense Oligonucleotides Targeting Tumor Necrosis Factor-{alpha} in Herpetic Stromal Keratitis Invest. Ophthalmol. Vis. Sci., December 1, 2003; 44(12): 5228 - 5234. [Abstract] [Full Text] [PDF]

				D. J. Stewart, R. C. Donehower, E. A. Eisenhauer, N. Wainman, A. K. Shah, C. Bonfils, A. R. MacLeod, J. M. Besterman, and G. K. Reid A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly Ann. Onc., May 1, 2003; 14(5): 766 - 774. [Abstract] [Full Text] [PDF]

				C. A. Farman and D. J. Kornbrust Oligodeoxynucleotide Studies in Primates: Antisense and Immune Stimulatory Indications Toxicol Pathol, January 1, 2003; 31(1_suppl): 119 - 122. [Abstract] [PDF]

				Y. Takei, K. Kadomatsu, H. Itoh, W. Sato, K. Nakazawa, S. Kubota, and T. Muramatsu 5'-,3'-Inverted Thymidine-modified Antisense Oligodeoxynucleotide Targeting Midkine. ITS DESIGN AND APPLICATION FOR CANCER THERAPY J. Biol. Chem., June 21, 2002; 277(26): 23800 - 23806. [Abstract] [Full Text] [PDF]

				L. Q. Sun, M. J. Cairns, E. G. Saravolac, A. Baker, and W. L. Gerlach Catalytic Nucleic Acids: From Lab to Applications Pharmacol. Rev., September 1, 2000; 52(3): 325 - 348. [Abstract] [Full Text] [PDF]

				E. M. McGuffie, D. Pacheco, G. M. R. Carbone, and C. V. Catapano Antigene and Antiproliferative Effects of a c-myc-targeting Phosphorothioate Triple Helix-forming Oligonucleotide in Human Leukemia Cells Cancer Res., July 1, 2000; 60(14): 3790 - 3799. [Abstract] [Full Text]

				R Haworth and A M Pilling The PCR assay in the preclinical safety evaluation of nucleic acid medicines Human and Experimental Toxicology, May 1, 2000; 19(5): 267 - 276. [Abstract] [PDF]

				A. M. Pilling The Role of the Toxicologic Pathologist in the Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals Toxicol Pathol, November 1, 1999; 27(6): 678 - 688. [Abstract] [PDF]